HANGZHOU, China and LONDON, UK I June 24, 2025 I MindRank, a clinical stage artificial intelligence (AI)-empowered drug discovery company, today announced ...

Company expands lead program into non-hereditary heterotopic ossification (NHHO), a condition with no approved treatments - ...

STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which ...

PHILADELPHIA, PA, USA I June 24, 2025 I GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved a 200 mg/mL ...

BELMONT, CA, USA I June 24, 2025 I Supercede Therapeutics, Inc., a startup biotech company focused on small molecule drug development, today announced ...

MUNICH, Germany I June 24, 2025 I Thermosome GmbH, a clinical-stage drug development company focused on targeted tumor therapies, today announced new, ...

OSAKA, Japan & BOSTON, MA, USA I June 23, 2025 I Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) and ...

The FB102-101 Phase 1b celiac disease study enrolled 32 subjects 3:1 randomized (24 on FB102 and 8 on placebo). Subjects received 4 doses of FB102 (10 mg/kg) and underwent a 16 day gluten challenge.

TOKYO, Japan & BASKING RIDGE, NJ, USA I June 23, 2025 I DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult ...

NEW YORK, NY, USA I June 23, 2025 I Formation Bio, an AI-native pharma company focused on accelerating drug development, today announced that its subsidiary ...

MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to ~20% Average Weight Loss Without a Weight Loss Plateau, and ...

Single doses of 450mg, 300mg and 150mg of CD388 conferred 76%, 61% and 58% protection, respectively, from symptomatic influenza over 24 weeks compared to placebo End of Phase 2 meeting request has ...